CFI-402257 NEW
| Price | $65 | $155 | $221 |
| Package | 1mg | 5mg | 10mg |
| Supply Ability: | 10g |
| Update Time: | 2026-05-15 |
Product Details
| Product Name: CFI-402257 | CAS No.: 1610759-22-2 |
| Purity: 98.33% | Supply Ability: 10g |
| Release date: 2026/05/15 |
Product Introduction
Bioactivity
| Name | CFI-402257 |
| Description | CFI-402257 (Luvixasertib) is a highly selective oral TTK (Mps1, Monopolar Spindle 1) kinase inhibitor that potently inhibits TTK kinase activity (Mps1 Ki = 0.09 nM；EC50 = 6.5 nM). It is intended for use in research on hepatocellular carcinoma and breast cancer. |
| In vitro | Methods: MHCC97L cells were treated with 100 nM CFI-402257 for 72 hours, followed by flow cytometric analysis of DNA content. Results: CFI-402257 induced a significant increase in the proportion of aneuploid cells. [1] |
| In vivo | Methods: MHCC97L-luc cells were implanted in BALB/cAnN-nu mice. Treatment commenced 2 weeks post-implantation when tumor formation initiated. CFI-402257 was administered orally via gavage at 30 mg/kg once daily for 4 consecutive weeks. Results: Tumor volume significantly decreased, and the number of pulmonary metastatic nodules markedly reduced. [1] Methods: A carotid artery wire injury model was established in C57BL/6 mice via carotid artery wire injury. Treatment commenced postoperatively with oral gavage of CFI-402257 at 30 mg/kg once daily for 28 consecutive days. Results: The area of newly formed endothelium and the intima-media ratio were significantly reduced, while re-endothelialization remained unaffected (confirmed by CD31 staining), demonstrating superiority over conventional drug-eluting stents. [2] |
| Storage | Store at low temperature,Keep away from moisture Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 37.7 mg/mL (75.61 mM), Sonication is recommended. |
| Keywords | TTK | Mps1 | CFI-402257 | CFI402257 | CFI 402257 |
| Inhibitors Related | Alectinib | Delgocitinib | Deucravacitinib | Ruxolitinib | GSK 3 Inhibitor IX | Soquelitinib | Oclacitinib maleate | Ibrutinib | BRD9876 | Vidarabine | Filgotinib | Gefitinib |
| Related Compound Libraries | Bioactive Compound Library | ReFRAME Related Library | Kinase Inhibitor Library | Tyrosine Kinase Inhibitor Library | Anti-Breast Cancer Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library | Anti-Cancer Drug Library | Anti-Cancer Active Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $4230.00 |
VIP2Y
|
TargetMol Chemicals Inc.
|
2026-05-21 | |
| $5930.00 |
VIP4Y
|
TargetMol Chemicals Inc.
|
2026-04-20 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY